BRAF as a potential therapeutic target in melanoma and other malignancies.

We apologize to our colleagues for our inability to cite multiple primary references due to space limitations. This work is supported in part by the McCabe Foundation, the Mary L. Smith Charitable Lead Trust, the Abramson Cancer Center of the University of Pennsylvania Pilot Projects Program, and Grant #IRG-78-002-26 from the American Cancer Society (all to D.A.T.), by the NIH grants CA-25874, CA-47159, CA-76674, and CA-10815 (to M.H.), and by funds from the Abramson Family Cancer Research Institute (D.A.T. and B.L.W.).

[1]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[2]  T. Takayama,et al.  Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. , 2001, Gastroenterology.

[3]  M. Stratton,et al.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.

[4]  D. Kelsell,et al.  Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas , 2003, British Journal of Cancer.

[5]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[6]  P. H. Moghaddam,et al.  Frequent loss of heterozygosity on chromosome 6p in uveal melanoma. , 1999, Human immunology.

[7]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[8]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[9]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[10]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[11]  W. Kolch,et al.  Nerve Growth Factor-mediated Activation of the Mitogen-activated Protein (MAP) Kinase Cascade Involves a Signaling Complex Containing B-Raf and HSP90* , 1996, The Journal of Biological Chemistry.

[12]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[13]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[14]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[15]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[16]  M. Herlyn,et al.  Activated ras. Yet another player in melanoma? , 1996, The American journal of pathology.

[17]  D. Woods,et al.  Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.

[18]  G. Bollag,et al.  Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.

[19]  Kun-Liang Guan,et al.  Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.

[20]  D. Tuveson,et al.  Targeting oncogene dependence and resistance. , 2003, Cancer cell.

[21]  H. Esumi,et al.  Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. , 1995, Gastroenterology.

[22]  F. Sommerer,et al.  Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.

[23]  Jeffrey W. Clark,et al.  Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma , 2002, American journal of clinical oncology.

[24]  M. Meyerson,et al.  Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.

[25]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[26]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[27]  S. Tóth,et al.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.

[28]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[29]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.